Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Mechanical Anisotropy Assessment in Kidney Cortex Using ARFI Peak Displacement: Preclinical Validation and Pilot In Vivo Clinical Results in Kidney Allografts.

Hossain MM, Detwiler RK, Chang EH, Caughey MC, Fisher MW, Nichols TC, Merricks EP, Raymer RA, Whitford M, Bellinger DA, Wimsey LE, Gallippi CM.

IEEE Trans Ultrason Ferroelectr Freq Control. 2019 Mar;66(3):551-562. doi: 10.1109/TUFFC.2018.2865203. Epub 2018 Aug 13.

PMID:
30106723
2.

Influence of diabetes on the foreign body response to nitric oxide-releasing implants.

Soto RJ, Merricks EP, Bellinger DA, Nichols TC, Schoenfisch MH.

Biomaterials. 2018 Mar;157:76-85. doi: 10.1016/j.biomaterials.2017.11.044. Epub 2017 Nov 30.

3.

Endothelial alterations in a canine model of immune thrombocytopenia.

LeVine DN, Cianciolo RE, Linder KE, Bizikova P, Birkenheuer AJ, Brooks MB, Salous AK, Nordone SK, Bellinger DA, Marr H, Jones SL, Fischer TH, Deng Y, Mazepa M, Key NS.

Platelets. 2019;30(1):88-97. doi: 10.1080/09537104.2017.1378807. Epub 2017 Nov 28.

PMID:
29182425
4.

Evaluation of Anthelmintic Resistance and Exhaust Air Dust PCR as a Diagnostic Tool in Mice Enzootically Infected with Aspiculuris tetraptera.

Kapoor P, Hayes YO, Jarrell LT, Bellinger DA, Thomas RD, Lawson GW, Arkema JD, Fletcher CA, Nielsen JN.

J Am Assoc Lab Anim Sci. 2017 May 1;56(3):273-289.

5.

An anti-αVβ3 antibody inhibits coronary artery atherosclerosis in diabetic pigs.

Maile LA, Busby WH, Xi G, Gollahan KP, Flowers W, Gafbacik N, Gafbacik S, Stewart K, Merricks EP, Nichols TC, Bellinger DA, Clemmons DR.

Atherosclerosis. 2017 Mar;258:40-50. doi: 10.1016/j.atherosclerosis.2017.01.030. Epub 2017 Jan 27.

PMID:
28189040
6.

Severe Hemophilia A in a Male Old English Sheep Dog with a C→T Transition that Created a Premature Stop Codon in Factor VIII.

Lozier JN, Kloos MT, Merricks EP, Lemoine N, Whitford MH, Raymer RA, Bellinger DA, Nichols TC.

Comp Med. 2016;66(5):405-411.

7.

Sustained correction of FVII deficiency in dogs using AAV-mediated expression of zymogen FVII.

Marcos-Contreras OA, Smith SM, Bellinger DA, Raymer RA, Merricks E, Faella A, Pavani G, Zhou S, Nichols TC, High KA, Margaritis P.

Blood. 2016 Feb 4;127(5):565-71. doi: 10.1182/blood-2015-09-671420. Epub 2015 Dec 23.

8.

Antioxidant Therapies for Ulcerative Dermatitis: A Potential Model for Skin Picking Disorder.

George NM, Whitaker J, Vieira G, Geronimo JT, Bellinger DA, Fletcher CA, Garner JP.

PLoS One. 2015 Jul 13;10(7):e0132092. doi: 10.1371/journal.pone.0132092. eCollection 2015.

9.

Oxidized LDL and Fructosamine Associated with Severity of Coronary Artery Atherosclerosis in Insulin Resistant Pigs Fed a High Fat/High NaCl Diet.

Nichols TC, Merricks EP, Bellinger DA, Raymer RA, Yu J, Lam D, Koch GG, Busby WH Jr, Clemmons DR.

PLoS One. 2015 Jul 6;10(7):e0132302. doi: 10.1371/journal.pone.0132302. eCollection 2015.

10.

A novel canine model of immune thrombocytopenia: has immune thrombocytopenia (ITP) gone to the dogs?

LeVine DN, Birkenheuer AJ, Brooks MB, Nordone SK, Bellinger DA, Jones SL, Fischer TH, Oglesbee SE, Frey K, Brinson NS, Peters AP, Marr HS, Motsinger-Reif A, Gudbrandsdottir S, Bussel JB, Key NS.

Br J Haematol. 2014 Oct;167(1):110-20. doi: 10.1111/bjh.13005. Epub 2014 Jul 8.

11.

Molecular characterization of cat factor XII gene and identification of a mutation causing factor XII deficiency in a domestic shorthair cat colony.

Bender DE, Kloos MT, Pontius JU, Hinsdale ME, Bellinger DA.

Vet Pathol. 2015 Mar;52(2):312-20. doi: 10.1177/0300985814532821. Epub 2014 May 2.

PMID:
24793828
12.

Targeted disruption of LDLR causes hypercholesterolemia and atherosclerosis in Yucatan miniature pigs.

Davis BT, Wang XJ, Rohret JA, Struzynski JT, Merricks EP, Bellinger DA, Rohret FA, Nichols TC, Rogers CS.

PLoS One. 2014 Apr 1;9(4):e93457. doi: 10.1371/journal.pone.0093457. eCollection 2014.

13.

Portal vein delivery of viral vectors for gene therapy for hemophilia.

Sherman A, Schlachterman A, Cooper M, Merricks EP, Raymer RA, Bellinger DA, Herzog RW, Nichols TC.

Methods Mol Biol. 2014;1114:413-26. doi: 10.1007/978-1-62703-761-7_27.

14.

Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A.

Du LM, Nurden P, Nurden AT, Nichols TC, Bellinger DA, Jensen ES, Haberichter SL, Merricks E, Raymer RA, Fang J, Koukouritaki SB, Jacobi PM, Hawkins TB, Cornetta K, Shi Q, Wilcox DA.

Nat Commun. 2013;4:2773. doi: 10.1038/ncomms3773.

15.

Animal models of hemophilia.

Sabatino DE, Nichols TC, Merricks E, Bellinger DA, Herzog RW, Monahan PE.

Prog Mol Biol Transl Sci. 2012;105:151-209. doi: 10.1016/B978-0-12-394596-9.00006-8. Review.

16.

Prevention of spontaneous bleeding in dogs with haemophilia A and haemophilia B.

Nichols TC, Raymer RA, Franck HW, Merricks EP, Bellinger DA, DeFriess N, Margaritis P, Arruda VR, Kay MA, High KA.

Haemophilia. 2010 May;16 Suppl 3:19-23. doi: 10.1111/j.1365-2516.2010.02255.x. Review.

17.

Safety of AAV factor IX peripheral transvenular gene delivery to muscle in hemophilia B dogs.

Haurigot V, Mingozzi F, Buchlis G, Hui DJ, Chen Y, Basner-Tschakarjan E, Arruda VR, Radu A, Franck HG, Wright JF, Zhou S, Stedman HH, Bellinger DA, Nichols TC, High KA.

Mol Ther. 2010 Jul;18(7):1318-29. doi: 10.1038/mt.2010.73. Epub 2010 Apr 27.

18.

A monoclonal antibody against alphaVbeta3 integrin inhibits development of atherosclerotic lesions in diabetic pigs.

Maile LA, Busby WH, Nichols TC, Bellinger DA, Merricks EP, Rowland M, Veluvolu U, Clemmons DR.

Sci Transl Med. 2010 Feb 10;2(18):18ra11. doi: 10.1126/scitranslmed.3000476.

19.

Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B.

Arruda VR, Stedman HH, Haurigot V, Buchlis G, Baila S, Favaro P, Chen Y, Franck HG, Zhou S, Wright JF, Couto LB, Jiang H, Pierce GF, Bellinger DA, Mingozzi F, Nichols TC, High KA.

Blood. 2010 Jun 10;115(23):4678-88. doi: 10.1182/blood-2009-12-261156. Epub 2010 Mar 24.

20.

Porcine and canine von Willebrand factor and von Willebrand disease: hemostasis, thrombosis, and atherosclerosis studies.

Nichols TC, Bellinger DA, Merricks EP, Raymer RA, Kloos MT, Defriess N, Ragni MV, Griggs TR.

Thrombosis. 2010;2010:461238. doi: 10.1155/2010/461238. Epub 2011 Feb 7.

21.

ARFI ultrasound for in vivo hemostasis assessment postcardiac catheterization, part I: preclinical studies.

Behler RH, Scola MR, Nichols TC, Bellinger DA, Gallippi CM.

Ultrason Imaging. 2009 Jul;31(3):153-8.

22.

Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency.

Nichols TC, Dillow AM, Franck HW, Merricks EP, Raymer RA, Bellinger DA, Arruda VR, High KA.

ILAR J. 2009;50(2):144-67. Review.

23.

In vivo response to vascular injury in the absence of factor IX: examination in factor IX knockout mice.

Gui T, Reheman A, Funkhouser WK, Bellinger DA, Hagaman JR, Stafford DW, Monahan PE, Ni H.

Thromb Res. 2007;121(2):225-34. Epub 2007 May 9.

PMID:
17490728
24.

Swine models of type 2 diabetes mellitus: insulin resistance, glucose tolerance, and cardiovascular complications.

Bellinger DA, Merricks EP, Nichols TC.

ILAR J. 2006;47(3):243-58. Review. No abstract available.

PMID:
16804199
25.

Long-term efficacy of adeno-associated virus serotypes 8 and 9 in hemophilia a dogs and mice.

Sarkar R, Mucci M, Addya S, Tetreault R, Bellinger DA, Nichols TC, Kazazian HH Jr.

Hum Gene Ther. 2006 Apr;17(4):427-39.

PMID:
16610930
26.

Porphyromonas gingivalis bacteremia induces coronary and aortic atherosclerosis in normocholesterolemic and hypercholesterolemic pigs.

Brodala N, Merricks EP, Bellinger DA, Damrongsri D, Offenbacher S, Beck J, Madianos P, Sotres D, Chang YL, Koch G, Nichols TC.

Arterioscler Thromb Vasc Biol. 2005 Jul;25(7):1446-51. Epub 2005 Apr 21.

PMID:
15845905
27.

Absence of a desmopressin response after therapeutic expression of factor VIII in hemophilia A dogs with liver-directed neonatal gene therapy.

Xu L, Nichols TC, Sarkar R, McCorquodale S, Bellinger DA, Ponder KP.

Proc Natl Acad Sci U S A. 2005 Apr 26;102(17):6080-5. Epub 2005 Apr 18.

28.

Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy.

Wang L, Calcedo R, Nichols TC, Bellinger DA, Dillow A, Verma IM, Wilson JM.

Blood. 2005 Apr 15;105(8):3079-86. Epub 2005 Jan 6.

29.

Intravenous administration of an AAV-2 vector for the expression of factor IX in mice and a dog model of hemophilia B.

Harding TC, Koprivnikar KE, Tu GH, Zayek N, Lew S, Subramanian A, Sivakumaran A, Frey D, Ho K, VanRoey MJ, Nichols TC, Bellinger DA, Yendluri S, Waugh J, McArthur J, Veres G, Donahue BA.

Gene Ther. 2004 Jan;11(2):204-13.

PMID:
14712305
30.

Reduced bleeding events with subcutaneous administration of recombinant human factor IX in immune-tolerant hemophilia B dogs.

Russell KE, Olsen EH, Raymer RA, Merricks EP, Bellinger DA, Read MS, Rup BJ, Keith JC Jr, McCarthy KP, Schaub RG, Nichols TC.

Blood. 2003 Dec 15;102(13):4393-8. Epub 2003 Aug 21.

31.

A gene-deleted adenoviral vector results in phenotypic correction of canine hemophilia B without liver toxicity or thrombocytopenia.

Ehrhardt A, Xu H, Dillow AM, Bellinger DA, Nichols TC, Kay MA.

Blood. 2003 Oct 1;102(7):2403-11. Epub 2003 Jun 12.

32.

Comparative response of plasma VWF in dogs to up-regulation of VWF mRNA by interleukin-11 versus Weibel-Palade body release by desmopressin (DDAVP).

Olsen EH, McCain AS, Merricks EP, Fischer TH, Dillon IM, Raymer RA, Bellinger DA, Fahs SA, Montgomery RR, Keith JC Jr, Schaub RG, Nichols TC.

Blood. 2003 Jul 15;102(2):436-41. Epub 2003 Mar 20.

33.

Neonatal or hepatocyte growth factor-potentiated adult gene therapy with a retroviral vector results in therapeutic levels of canine factor IX for hemophilia B.

Xu L, Gao C, Sands MS, Cai SR, Nichols TC, Bellinger DA, Raymer RA, McCorquodale S, Ponder KP.

Blood. 2003 May 15;101(10):3924-32. Epub 2003 Jan 16.

34.

Thrombus formation with rehydrated, lyophilized platelets.

Fischer TH, Merricks EP, Bode AP, Bellinger DA, Russell K, Reddick R, Sanders WE, Nichols TC, Read MS.

Hematology. 2002 Dec;7(6):359-69.

PMID:
12475741
35.

Proteasome inhibition ablates activation of NF-kappa B in myocardial reperfusion and reduces reperfusion injury.

Pye J, Ardeshirpour F, McCain A, Bellinger DA, Merricks E, Adams J, Elliott PJ, Pien C, Fischer TH, Baldwin AS Jr, Nichols TC.

Am J Physiol Heart Circ Physiol. 2003 Mar;284(3):H919-26. Epub 2002 Nov 7.

36.

The Chapel Hill hemophilia A dog colony exhibits a factor VIII gene inversion.

Lozier JN, Dutra A, Pak E, Zhou N, Zheng Z, Nichols TC, Bellinger DA, Read M, Morgan RA.

Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):12991-6. Epub 2002 Sep 19.

37.

Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy.

Herzog RW, Fields PA, Arruda VR, Brubaker JO, Armstrong E, McClintock D, Bellinger DA, Couto LB, Nichols TC, High KA.

Hum Gene Ther. 2002 Jul 20;13(11):1281-91.

PMID:
12162811
38.

Splenic clearance mechanisms of rehydrated, lyophilized platelets.

Fischer TH, Merricks E, Bellinger DA, Hayes PM, Smith RS, Raymer RA, Read MS, Nichols TC, Bode AP.

Artif Cells Blood Substit Immobil Biotechnol. 2001 Nov;29(6):439-51.

PMID:
11795630
39.

Intratracheal administration of recombinant human factor IX (BeneFix) achieves therapeutic levels in hemophilia B dogs.

Russell KE, Read MS, Bellinger DA, Leitermann K, Rup BJ, McCarthy KP, Keith JC Jr, Khor SP, Schaub RG, Nichols TC.

Thromb Haemost. 2001 Mar;85(3):445-9.

PMID:
11307812
40.

Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver.

Wang L, Nichols TC, Read MS, Bellinger DA, Verma IM.

Mol Ther. 2000 Feb;1(2):154-8.

41.

Reduction in atherosclerotic lesion size in pigs by alphaVbeta3 inhibitors is associated with inhibition of insulin-like growth factor-I-mediated signaling.

Nichols TC, du Laney T, Zheng B, Bellinger DA, Nickols GA, Engleman W, Clemmons DR.

Circ Res. 1999 Nov 26;85(11):1040-5.

PMID:
10571535
42.

Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors.

Snyder RO, Miao C, Meuse L, Tubb J, Donahue BA, Lin HF, Stafford DW, Patel S, Thompson AR, Nichols T, Read MS, Bellinger DA, Brinkhous KM, Kay MA.

Nat Med. 1999 Jan;5(1):64-70.

PMID:
9883841
43.

Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector.

Herzog RW, Yang EY, Couto LB, Hagstrom JN, Elwell D, Fields PA, Burton M, Bellinger DA, Read MS, Brinkhous KM, Podsakoff GM, Nichols TC, Kurtzman GJ, High KA.

Nat Med. 1999 Jan;5(1):56-63.

PMID:
9883840
44.

Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia.

Monahan PE, Samulski RJ, Tazelaar J, Xiao X, Nichols TC, Bellinger DA, Read MS, Walsh CE.

Gene Ther. 1998 Jan;5(1):40-9.

45.

von Willebrand factor does not influence atherogenesis in arteries subjected to altered shear stress.

Nichols TC, Bellinger DA, Reddick RL, Koch GG, Sigman JL, Erickson G, du Laney T, Johnson T, Read MS, Griggs TR.

Arterioscler Thromb Vasc Biol. 1998 Feb;18(2):323-30. Review.

PMID:
9485000
46.

Oral contraceptives and hormone replacement therapy do not increase the incidence of arterial thrombosis in a nonhuman primate model.

Bellinger DA, Williams JK, Adams MR, Honoré EK, Bender DE.

Arterioscler Thromb Vasc Biol. 1998 Jan;18(1):92-9.

PMID:
9445261
47.

Lack of persistence of E1- recombinant adenoviral vectors containing a temperature-sensitive E2A mutation in immunocompetent mice and hemophilia B dogs.

Fang B, Wang H, Gordon G, Bellinger DA, Read MS, Brinkhous KM, Woo SL, Eisensmith RC.

Gene Ther. 1996 Mar;3(3):217-22.

PMID:
8646552
48.

FISH mapping of the porcine vWF gene to chromosome 5q21 extends synteny homology with human chromosome 12.

Sjöberg A, Seaman WT, Bellinger DA, Griggs TR, Nichols TC, Chowdhary BP.

Hereditas. 1996;124(2):199-202. No abstract available.

49.

Hepatic contrast enhancement at CT: influence of intravenous glucagon in a canine model.

Warshauer DM, Hiken JN, Molina PL, Hackney SL, Bellinger DA, Lee JK.

Radiology. 1995 Nov;197(2):365-8.

PMID:
7480678
50.

Gene therapy for hemophilia B: host immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expression.

Fang B, Eisensmith RC, Wang H, Kay MA, Cross RE, Landen CN, Gordon G, Bellinger DA, Read MS, Hu PC, et al.

Hum Gene Ther. 1995 Aug;6(8):1039-44.

PMID:
7578416

Supplemental Content

Loading ...
Support Center